Documenting the Global Burden of Cardiovascular Disease:
A Major Achievement but Still Work in Progress

Running title: Yusuf et al.; Global burden of cardiovascular diseases

Salim Yusuf, DPhil, FRCPC, FRSC, OC\(^1\); Martin McKee, CBE, MD, FRCP\(^2\)

\(^1\)Population Health Research Institute, McMaster University and Hamilton Health Sciences
Hamilton, Ontario, Canada; \(^2\)London School of Hygiene and Tropical Medicine, London,
United Kingdom

Address for Correspondence:
Salim Yusuf, DPhil, FRCPC, FRSC, OC
Population Health Research Institute, DBCVSRI
237 Barton Street East
Hamilton, ON, Canada L8L 2X2
Tel: 905-527-7327
Fax: 905-297-3781
E-mail: yusufs@mcmaster.ca


Key words: global, Editorial, cardiovascular disease, myocardial infarction, stroke
The publication of the 1990 Global Burden of Disease (GBD) was a seminal moment for international health.\(^1\) In a world characterized by what has been termed a “scandal of ignorance”,\(^2\) where most peoples’ existence was never recorded, the authors undertook the heroic task of estimating not only how many people were dying and from what conditions but also how many were living with disability. By combining these measures to create the Disability Adjusted Life Year (DALY), they changed the global health discourse forever. The task was enormous. They had to include all countries, including many that had attracted virtually no attention from health researchers and which lacked vital registration systems. They scoured the world for data, extracting information from dusty archives and analyzed surveys that had been forgotten.

However, existing data only went so far; alternatives were needed. The authors created complex, although for some virtually incomprehensible models that established relationships in countries with data for variables such as national income, and patterns of disease, and then extrapolated to countries, regions or for conditions where data were unavailable to fill the many gaps.\(^3\) They also developed ambitious methodological and empirical approaches to understand associations between mortality and the much less well researched disability, and to measure the contribution of different disease states to both.\(^4\)

These efforts in turn have stimulated a massive increase in data collection, with expansions in vital registration systems, sentinel surveillance sites,\(^5\) and methodological refinements of instruments such as verbal autopsy.\(^6\) As a result, the 2010 GBD took our understanding of the health of the world’s population to a new level\(^7\) although, as the accompanying papers in this issue of Circulation demonstrate, there are still many issues to be resolved.\(^8-9\) Yet the analyses presented raise important issues for policy and action in several areas.
First, these papers confirm the success in reducing mortality from cardiovascular disease (CVD) in most rich countries. These are remarkable public health achievements. Yet, progress in other parts of the world has been slow or non-existent. In Eastern Europe and parts of Asia the situation worsened (although it may be improving at long last in Russia). Clearly it is important to understand factors associated with success so that they can be emulated elsewhere. Research such as that using the IMPACT model has been crucial, distinguishing the impact of different preventive and treatment measures. These studies show that about 90% of the decline could be explained and of this about half can be attributed to improved treatments, with the other half to reductions in risk factors such as smoking, cholesterol and BP levels, although this has been counterbalanced to some extent, by increasing obesity and diabetes. Many of the gains can be attributed to the increased use of simple medicines for secondary prevention, better management of acute coronary syndromes and improved management of heart failure and hypertension.

The message for low and middle income countries (LMIC) is clear. Enormous progress can be made by implementing a comprehensive package of simple, low cost policies. Some countries, such as New Zealand, have set a target to eliminate smoking by 2020. This should now be the gold standard. Anything less displays a profound lack of ambition. Action is also needed on diet. Many LMIC are being flooded with energy dense food and drink, marketed aggressively by multinational corporations, or with unhealthy products made in large quantities as a consequence of market-distorting subsidies for farmers in wealthy countries, such as high fructose corn syrup. Public health policies (on tobacco, diet and activity), based on sound evidence are required and must be accompanied by improved access to inexpensive but effective medications. This is not just a matter of money. Even in many of the wealthiest countries control of hypertension or use of simple, proven and inexpensive medications for secondary prevention
is sub-optimal.\textsuperscript{15} Where success has been achieved it has involved the development of culturally and contextually appropriate approaches to health care delivery, reaching out to those most disadvantaged to minimize disparities.\textsuperscript{16}

Second, most figures produced by the GBD are from models populated primarily by data from rich countries as vital registration systems are mostly confined to high and upper middle income countries. These have also been the setting for the most research in cardiovascular disease.\textsuperscript{17} Consequently, it is largely a matter of conjecture as to whether such estimates are sufficiently reflective of middle and low income countries, from which there is relatively modest information.

Countries in a region with sufficient infrastructure in place to collect data may also have better functioning health systems, than in their neighbours that are unable to provide data. This is a major problem when assessing changes in CVD. Health systems to document disease burden, prevent, and treat common non-communicable diseases (NCDs) should be essential components of the international development agenda. The Millennium Development Goals, which have driven donor efforts since 2000, did not include non-communicable disease, in large part because of a lack of relevant data on the NCD burden.\textsuperscript{18} This contrasts with maternal and child health, which were included because they were monitored periodically in the Demographic and Health Surveys in those countries lacking vital registration.

The situation is, however, changing. Sentinel surveillance sites, such as those in the INDEPTH network, have shown the alarming growth in cardiovascular risk factors in some low income settings. Research using the IMPACT model in some middle income countries (MIC) show, while improved prevention and treatment are making a difference, they are failing to keep up with the rapidly worsening risk factors.\textsuperscript{19} Finally, recent data from the first round of follow up
of the Prospective Urban and Rural Epidemiology Study (PURE), tracking 55,000 individuals in 628 communities in 17 countries at all levels has documented higher mortality and CVD despite lower risk factor burden in poor countries. This was paralleled by lower rates of use of secondary prevention medications and hypertension in poorer countries and suggests that these countries have less well functioning healthcare systems compared to richer countries.

It is, however, essential to recognize that models of care used in high income countries (HIC) cannot automatically be transferred to LMIC, where the context, and especially, access to resources, is very different. For example, most HIC spend about 10% (ranging from 8% to as high as 18% in the USA) of their GDP on health whereas LMIC spend generally spend only about 2% to 5% of their (much lower) GDPs on health care. Instead, effective solutions at much lower costs are needed for LMIC. For example, in countries with few health professionals, most tasks can be shifted to mid-level non-physician health workers (NPHW) rather than depend on the handful of often grossly overloaded physicians and nurses. CVD control tasks that can be shifted include screening for hypertension, ongoing management of individuals with stable vascular disease with simple drugs and lifestyle advice, identifying individuals with prevalent CVD and diabetes, and communicating that these diseases require lifelong medications and lifestyle changes, even in asymptomatic individuals.

Yet while NPHW can make as valid decisions as physicians regarding prevention and treatment pathways for CVD, in many countries there are legislative barriers to the use of NPHW (only physicians may be allowed to prescribe drugs in many countries or patients expect that decisions on treatments made by physicians are “superior”). These barriers can be overcome through changes in legislation that allow NPHW the ability to prescribe a small range of simple, effective and safe drugs, to educate patients to accept NPHWs and to combine these with
strategies to improve adherence. Further, NPHWs can visit patients at their homes (as is done for immunizations and TB and malaria control in some countries), thereby improving access of patients to health care, and simultaneously reducing their out of pocket costs related to travelling long distances to see physicians. This also avoids or minimizes their expenditure on physician fees, and loss of time (and income) from missing work. A further challenge, in some LMIC, is the presence of different health belief systems. Changes require visionary leadership and while some LMICs have achieved much in implementing evidence-based policies on health care delivery, supported by effective institutions and governance, most have not.

A parallel goal of the GBD project has been to quantify the contributions of specific health behaviours and risk factors to CVD (and other common conditions) as described previously. However, due to an over-reliance on the epidemiologic data, some of the estimates of the degree of attribution of certain risk factors are questionable. While estimates of the impact of tobacco use on CVD are relatively robust, the impact of cholesterol on CVD is likely a major underestimate as the evidence from randomized clinical trials (RCTS) indicating clear reductions in stroke are ignored (whereas the lack of association of cholesterol with stroke seen in some epidemiologic studies is given undue weight in the GBD). Conversely, the importance of BP as a “modifiable” cause of CVD may be over-estimated as there is as yet no evidence that lowering blood pressure per se in those with a systolic blood pressure < 140 mm Hg reduces CVD. The large impact attributed to salt intake is a “triple extrapolation”, with assumptions that the association of sodium intake to blood pressure is linear (contradicted by a large recent study), that the association between sodium intake and CVD is continuous (which has been challenged) and that sodium reduction will lower CVD, which has never been demonstrated in RCTS. While there is ecologic evidence from countries where sodium consumption was
historically very high (> 8 gm of sodium/day),\textsuperscript{30} that reductions in salt consumption reduce stroke and perhaps other CVD, evidence that further reducing sodium from population levels of sodium that are already below 5 g/d, will lead to a reduction in CVD is not available. Therefore, the potential impact of sodium reduction on CVD in the GBD study is likely to be substantially overestimated (perhaps by as much as 5 or 10-fold). Similarly, the claims that increasing fish or fish oils in the diet will reduce CVD has been refuted by large recent trials,\textsuperscript{31} and the epidemiologic data that fish consumption will reduce CVD are not robust. Therefore, quantification of the impact of some of the health behaviours and risk factors on the global burden of CVD needs to be revisited as more or better data accrue. Of course, none of these concerns diminish the enormous contributions of the GBD project towards setting an expanded global agenda that includes CVD and other NCDs.

Undoubtedly, there will be future cycles of the GBD. What can be done to improve the reliability of future estimates? First, we need very large, studies (and by necessity ultra-simple ones) conducted in as many LMIC as possible, using innovative designs (e.g. representative household surveys and obtaining information from key respondents) that can document morbidity and mortality and relate them to simple risk factors and health behaviours. By comparing behaviours of individuals who had suffered an event with those who did not, the impact of the risk factors on specific conditions can be studied efficiently in representative populations in different LMIC. Information from some of the large ongoing prospective epidemiologic studies such as the Kadoorie study in China, which includes multiple provinces,\textsuperscript{32} the PURE study, now in 21 countries\textsuperscript{20} and the IN DEPTH network in 18 countries\textsuperscript{33} will also help provide new information that will make future estimates of the disease burden and their causes more reliable.
Ultimately, the generation of reliable data on disease burden should be one of the cornerstones of developing evidence-based global, region and country specific public health strategies for CVD prevention. Such information is essential to inform the development of appropriate health care systems that are effective and responsive to the needs of sub-national administrative units within each country, and across various countries in each region. It is no coincidence that countries that have good documentation of their mortality and morbidity are also the ones that develop policies and care systems that improve health in their countries. Such information is also critical for making a case to governments and international donors for appropriate investments in the control of CVD and other NCDs. Such new information will make future GBD estimates less reliant on complex modeling, more transparent and likely more robust. The dual strategy of simultaneously obtaining more robust data globally with continuing efforts to synthesize them will underpin the global health agenda and will facilitate appropriate health policies and actions.

Conflict of Interest Disclosures: None.

References:


Documenting the Global Burden of Cardiovascular Disease: A Major Achievement but Still
Work in Progress
Salim Yusuf and Martin McKee

Circulation. published online February 26, 2014;
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2014 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/early/2014/02/26/CIRCULATIONAHA.114.008302

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org/subscriptions/